Volume 7, Issue 7


In this issue:

Among the many controversies surrounding mRNA vaccination, one of particular importance to PLWH already experiencing immune dysregulation is, can these vaccines provide a sufficient and durable protective immune response against COVID-19? How attenuated is the vaccine’s immunogenicity when compared to that in people without HIV? What does the current evidence say about available therapeutics?

Those are some of the questions addressed by Nurse Practitioner Diane Kanjilal, Manager of the Infectious Disease Clinical Research Unit at Massachusetts General Hospital, in this issue of eHIV Review. 

Learning objectives:

  • Describe the attenuated response to COVID-19 mRNA vaccines among PLWH and the increased risk of hospitalization and mortality for PLWH who develop COVID-19.  
  • Discuss the nature and frequency of the postacute sequalae of SARS-CoV-2 infection (PASC) syndrome among people living with HIV. 


Diane Kanjilal, FNP-BC
Diane Kanjilal, FNP-BC

Family Nurse Practitioner
Clinical Research Nurse Manager, Infectious Diseases Clinical Research Unit
Massachusetts General Hospital
Boston, MA

Program Directors:

Justin Alves, RN, ACRN, CARN

Nurse Educator – Office Based Addiction Treatment, Training and Technical Assistance Program
Boston Medical Center
Boston, Massachusetts

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: May 26, 2022
Expiration date: May 25, 2024